Birth length of at least 50 cm may bump up breast ca risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

An increase in birth length by 2 cm is associated with a 9% increase in breast cancer risk, according to a study reported in PLoS Medicine, online. Isabel dos Santos Silva, MD, PhD, a professor of epidemiology at the London School of Hygiene and Tropical Medicine and colleagues, examined 32 studies involving 22,058 breast cancer cases.

An increase in birth length by 2 cm is associated with a 9% increase in breast cancer risk, according to a study reported in PLoS Medicine, online. Isabel dos Santos Silva, MD, PhD, a professor of epidemiology at the London School of Hygiene and Tropical Medicine and colleagues, examined 32 studies involving 22,058 breast cancer cases.

The researchers found the strongest link between breast cancer and birth size occurred between a length at birth of greater than or equal to 50 cm. In addition to length, a 0.5 kg increment in birth weight, greater than or equal to 3.5 kg, was associated with an estimated 7% increase in the risk of breast cancer (PLoS Med 5: e193, 2008).

“Assuming causality, we estimated that about 5% of all breast cancers in developed countries could be attributable to high birth size,” the researchers wrote. They also said the association between birth size and breast cancer appeared to be largely independent of known risk factors.

“Further research is needed to unravel the biological mechanisms underlying the birth size-breast cancer association,” wrote Dr. Silva’s group.

In an accompanying editorial, Pagona Lagiou, MD, PhD, and Dimitrios Trichopoulos, MD, PhD, both from the epidemiology department at the Harvard School of Public Health in Boston, said while the relative size of the eff ects is small, the individual studies driving the conclusion were of sound epidemiological design. The research relied on objectively documented birth size parameters, allowing little room for bias (PLoS Med 5: e194, 2008).

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content